Innate Pharma (IPHA) Total Liabilities (2017 - 2025)
Innate Pharma's (IPHA) quarterly Total Liabilities came in at $73.0 million in Q4 2025, down 38.48% YoY from $118.7 million in Q4 2024, and down 30.6% on a QoQ basis from $105.2 million in Q2 2025.
Innate Pharma (IPHA) Total Liabilities (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Total Liabilities data on file, last reported at $73.0 million in Q4 2025.
- Quarterly Total Liabilities fell 38.48% year-over-year to $73.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.0 million (down 38.48% YoY) and the FY2025 annual result came in at $73.0 million, down 38.48% from the prior year.
- Total Liabilities fell to $73.0 million in Q4 2025, from $105.2 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $320.6 million in Q2 2021 to a low of $73.0 million in Q4 2025.
- A 5-year average of $199.4 million and a median of $195.9 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities sank 99.9% — and 2022, when it declined 6.66%.
- Tracing IPHA's Total Liabilities over 5 years: stood at $306.0 million in 2021, then plunged by 33.55% to $203.3 million in 2022, then fell by 7.3% to $188.5 million in 2023, then sank by 37.04% to $118.7 million in 2024, then slumped by 38.48% to $73.0 million in 2025.
- The last three Total Liabilities figures came in at $73.0 million (Q4 2025), $105.2 million (Q2 2025), and $118.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | 73.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.01 Mn |
| Jun 30, 2025 | 105.20 Mn |
| Dec 31, 2024 | 118.68 Mn |
| Jun 30, 2024 | 163.15 Mn |
| Dec 31, 2023 | 188.49 Mn |
| Jun 30, 2023 | 216.75 Mn |
| Dec 31, 2022 | 203.33 Mn |
| Jun 30, 2022 | 299.23 Mn |
| Dec 31, 2021 | 306.01 Mn |
| Jun 30, 2021 | 320.60 Mn |
| Dec 31, 2020 | 366.54 Mn |
| Jun 30, 2020 | 333.07 Bn |
| Dec 31, 2019 | 444.26 Mn |
| Dec 31, 2018 | 516.27 Mn |
| Dec 31, 2017 | 303.92 Mn |